ST2 in Pulmonary Disease - 13/03/15
Doi : 10.1016/j.amjcard.2015.01.040
Ednan K. Bajwa, MD, MPH a, ⁎ 
, Alexandre Mebazaa, MD, PhD b, James L. Januzzi, MD c
, Alexandre Mebazaa, MD, PhD b, James L. Januzzi, MD c a Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
c Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
b Department of Anesthesiology and Critical Care Medicine, University of Paris Diderot, Paris, France
∗Address for reprints: Ednan K. Bajwa, MD, MPH, Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Bulfinch 148, 55 Fruit St, Boston, Massachusetts 02114.
Abstract |
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of the ST2 pathway in clinical disease, including evidence that sST2 could be a useful biomarker in both allergic and nonallergic pulmonary disease.
Le texte complet de cet article est disponible en PDF.Plan
| Publication of this supplement was supported by funding from Critical Diagnostics, San Diego, CA. |
|
| Statement of author disclosure: Please see the Author Disclosures section at end of this article. |
© 2015
Elsevier Inc. Tous droits réservés.
Vol 115 - N° 7S
P. 44B-47B - avril 2015 Retour au numéro
Article précédent
- ST2 and Multimarker Testing in Acute Decompensated Heart Failure
- Alexandre Mebazaa, Salvatore Di Somma, Alan S. Maisel, Antoni Bayes-Genis
- ST2 in Stable and Unstable Ischemic Heart Diseases
- A. Mark Richards, Salvatore Di Somma, Thomas Mueller
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?